Looking ahead, the continued refinement of PSMA-based techniques, combined with improved understanding of their optimal clinical implementation, promises to further enhance our ability to provide precise, personalized care for patients with prostate cancer. This evidence concerns the gene FOLH1 and Familial prostate cancer.